Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)
Ovid Therapeutics' (OVID) quarterly Current Deferred Revenue came in at $718000.0 in Q3 2025, little changed quarter-over-quarter from $718000.0 in Q2 2025.
Powered by 
Analysis
Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Ovid Therapeutics (OVID) has reported Current Deferred Revenue for 2 consecutive years, with $718000.0 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $718000.0; the trailing twelve-month figure through Sep 2025 stood at $718000.0 (changed N/A YoY), and the FY2020 full-year result was $2.2 million, changed N/A from the prior year.
- Current Deferred Revenue was little changed at $718000.0 in Q3 2025 per OVID's latest filing, from $718000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $718000.0 in Q2 2025 and bottomed at $718000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 718,000.00 |
| Jun 30, 2025 | 718,000.00 |
| Dec 31, 2020 | 2.21 Mn |
| Sep 30, 2020 | 3.15 Mn |